The endothelin-1 vasoconstrictor pathway contributes to age-related elevations in resting peripheral vascular tone primarily through activation of the endothelin subtype A (ET A ) receptor. However, the regulatory influence of ET A -mediated vasoconstriction during exercise in the elderly is unknown. Thus, in 17 healthy volunteers (n = 8 young, 24 ± 2 years; n = 9 old, 70 ± 2 years), we examined leg blood flow, mean arterial pressure , leg arterial-venous oxygen (O 2 ) difference, and leg O 2 consumption (VO 2 ) at rest and during knee-extensor exercise before and after intra-arterial administration of the ET A antagonist BQ-123. During exercise, BQ-123 administration increased leg blood flow to a greater degree in the old (+29 ± 5 mL/min/W) compared with the young (+16 ± 3 mL/min/W). The increase in leg blood flow with BQ-123 was accompanied by an increase in leg VO 2 in both groups, suggesting a reduced efficiency following ET A receptor blockade. Together, these findings have identified an age-related increase in ET Amediated vasoconstrictor activity that persists during exercise, suggesting an important role of this pathway in the regulation of exercising skeletal muscle blood flow and maintenance of arterial blood pressure in the elderly.
regulation between resting and exercising states, has long been a topic of investigation. Although there are a host of pathways that collectively contribute to increased vascular tone in the elderly, changes in the endothelin-1 (ET-1) pathway may be particularly relevant to this age-related adaptation. Indeed, there is evidence from both animal and human studies for an increase in the activity of the ET-1 pathway with advancing age (12) (13) (14) , which has been linked to the ageassociated reduction in resting skeletal muscle blood flow (15, 16) via the endothelin subtype A (ET A ) receptor pathway (16, 17) .
Despite clear evidence implicating ET-1 as an important contributor to elevated resting vascular tone in the elderly, no studies to date have sought to examine the role of the ET A pathway in the regulation of exercising skeletal muscle blood flow with advancing age. Thus, this study evaluated the cardiovascular responses to kneeextensor exercise before and after inhibition of the ET A receptor via intra-arterial administration of BQ-123 in the exercising limb. We hypothesized that (a) ET A receptor blockade would enhance resting skeletal muscle blood flow in old, but not in young; (b) ET A receptor blockade during exercise would enhance skeletal muscle blood flow and reduce arterial blood pressure to a greater extent in old individuals, compared with their younger counterparts.
Methods

Participants
Eight young (24 ± 2 yrs) and nine old (70 ± 2 yrs) healthy participants were enrolled in this study. A subset of the data from the young participants have been reported previously (18) and are presented for the purpose of comparison in this study. All participants were nonsmokers and were normally active. Participants were not taking any prescription medication and were free of overt cardiovascular disease, as indicated by a health history. Protocol approval and written informed consent were obtained according to the University of Utah and the Salt Lake City Veterans Affairs Medical Center Institutional Review Board requirements. All data collection took place at the Veterans Affairs Salt Lake City Geriatric, Research, Education, and Clinical Center in the Utah Vascular Research Laboratory .
Protocols
Participants reported to the Utah Vascular Research Laboratory at 0800 on the experimental day. After 30 minutes of supine rest, two catheters (common femoral artery [CFA] and femoral vein) were placed using sterile technique, as described previously (19) (20) (21) . After catheter placement, participants rested for about 30 minutes and then underwent the protocol as outlined in Figure 1 . Participants reported to the lab in the fasted state and were given a small, standardized meal (1/2 cup of corn flakes and 1/2 cup of skim milk) 10 minutes prior to the start of the control (saline) and the ET A receptor blockade (BQ-123) trials ( Figure 1 ). All data collection took place with participants in a semirecumbent position (60° reclined), and all studies were performed in a thermoneutral environment.
Due to the long-lasting effects of BQ-123, the drug administration portion of the protocol always occurred after the saline portion of the protocol. Thus, to determine whether the observed changes in leg blood flow and mean arterial pressure (MAP) were the consequence of an exercise ordering effect, rather than the effect of the drug per se, participants returned to the laboratory on a separate day to undergo an exercise time control study. For this visit, catheters were not placed, and no drugs were administered. Apart from these differences, the timeline for this time control study was identical to the drug infusion day, with the addition of leg blood flow measurements immediately before and after a light meal to examine possible postprandial hemodynamic effects.
Study Drugs
Thigh volumes were determined anthropometrically and then used for the calculation of drug dosing. A selective ET A receptor antagonist (BQ-123 Clinalfa, Calbiochem-Novabiochem, Läufelfingen, Figure 1 . Experimental protocol. Arrows indicate points at which leg blood flow was recorded and arterial and venous blood samples were obtained.
Switzerland) was prepared in normal saline (0.9% NaCl) and administered intra-arterially (CFA) at 10 nmol/min/L of thigh volume (infusion rates 0.8-1.5 mL/min). This dose has been documented to induce an apparent plateau in vasodilation in both the forearm (22, 23) and quadriceps (15) , without affecting MAP. BQ-123 has been documented to have a high affinity for the ET A receptor (24) and to effectively counteract the vasoconstrictor effect of ET-1 infusion in the human forearm (25) . During the control trial, normal saline (0.9% NaCl) was administered intra-arterially into the CFA at the same infusion rates as BQ-123.
Exercise Model
The knee-extensor paradigm implemented in this study has been described previously (4, (26) (27) (28) . Briefly, participants were seated in a semirecumbent position on an adjustable chair with a cycle ergometer (model 828E; Monark Exercise AB, Vansbro, Sweden) positioned behind them. Resistance was created by applying friction to the flywheel, which was turned by the participant via a metal bar connected to the crank arm of the ergometer and a metal boot in which the participant's foot was placed. Participants exercised for 3 minutes at 0 (ie, unloaded), 5, 10, and 15 W, as well as 20%, 40%, 60%, and 80% of their predetermined maximal work rate (WR max ) while maintaining 60 contractions per minute. A 3-minute recovery period was given following three successive exercise bouts ( Figure 1 ). Both absolute and relative work rates were incorporated into the protocol to address the dichotomy that limb blood flow is regulated predominantly by absolute work performed (29) , whereas exercise-induced changes in MAP are dependent upon relative exercise intensity (10, 30) .
Measurements
Ultrasound Doppler assessments. Measurements of CFA blood velocity and vessel diameter were performed in the infused leg using a Logiq 7 ultrasound Doppler system (GE Medical Systems, Milwaukee, WI) operating in duplex mode. The Logic 7 was equipped with a linear array transducer operating at an imaging frequency of 14 MHz. The CFA was insonated 2-3 cm proximal to the bifurcation of the CFA into the superficial and deep branches. The blood velocity profile was obtained using the same transducer with a Doppler frequency of 5 MHz, operated in the highpulsed repetition frequency mode (2-25 kHz). Care was taken to avoid aliasing the blood velocity spectra by using scale adjustments, especially during exercise. All blood velocity measurements were obtained with the probe appropriately positioned to maintain an insonation angle of 60° or less (31) . The sample volume was maximized according to vessel size and was centered within the vessel on the basis of real-time ultrasound visualization. At all sample points, arterial diameter (cm) and angle-corrected, time-averaged, and intensity-weighted mean blood velocity (V mean ) values were calculated using commercially available software (Logic 7). Using measured arterial diameter and V mean , leg blood flow was calculated according to the equation: leg blood flow (mL/min) = (V mean × π (vessel diameter/2) 2 × 60).
MAP, vascular conductance, and heart rate assessment. Arterial blood pressure measurements were collected continuously from the indwelling catheter placed in the CFA with the pressure transducer placed at the level of the catheter (Transpac IV, Abbott Laboratories). MAP (mmHg) was calculated as diastolic arterial pressure + (arterial pulse pressure × 0.33). On the time control study day, MAP was determined noninvasively using finger photoplethysmography (Finometer, Finapres Medical Systems BV, Amsterdam,
The Netherlands). Leg vascular conductance was calculated as leg blood flow / MAP. Heart rate was monitored from a standard threelead electrocardiogram recorded in duplicate on the data acquisition device (Biopac, Goleta, CA) and the Logic 7.
Blood chemistry A lipid panel was obtained for all participants by standard techniques.
In the last 30 seconds of each exercise intensity, femoral arterial and venous blood samples (3-4 mL) were collected. One milliliter of arterial and venous blood were presented anaerobically to a GEM 4000 bloodgas analyzer and co-oximeter (Instrumentation Laboratories, Bedford, MA) to obtain arterial and venous total hemoglobin (tHb) oxyhemoglobin saturation (SO 2 ), partial pressure of oxygen (PO 2 ), hematocrit (hct), lactate, and pH. Arterial and venous blood oxygen content (CaO 2 and CvO 2 ; mL/dL) were calculated as the following: Blood oxygen content (mL/dL) = 1.39 (tHb) × (SO 2 /100) + 0.003 × PO 2 . Leg oxygen consumption (VO 2 ; mL/min) was calculated as the following: VO 2 (mL/ min) = (C A O 2 − C V O 2 ) × leg blood flow. The remaining blood was centrifuged, and plasma stored at −80°C until analysis. Plasma ET-1 concentrations were evaluated via quantitative enzyme immunoassay (R&D Systems, Minneapolis, MN), with a sensitivity of less than 1 pg/mL. Intra-assay and interassay coefficient of variation were 4.5% and 5.5%, respectively. Using arterial (C A ) and venous (C V ) plasma ET-1 or lactate concentrations, with corrections for leg blood flow, "net ET-1 release" and "net lactate release" were calculated (18, 32) according to the following equation: Net ET-1 (ng/min) or lactate release (mmol/min) = (C V − C A ) × (leg blood flow × ((101 − (hct/100))).
Data Analysis and Statistics
BQ-123-induced changes in leg blood flow, MAP, and leg vascular conductance were calculated as the difference between the BQ-123 trial value and the saline trial value. Statistics were performed with the use of commercially available software (SigmaStat 3.10; Systat Software, Point Richmond, CA). Sample size calculations were performed using the estimated effect size and standard deviation for BQ-induced changes in leg blood flow and leg vascular conductance. For these outcome measures, it was estimated that six participants per group were needed for a desired power of 0.8 (α = 0.05). A 2 × 9 repeated measure analysis of variance was used to identify significant changes in measured variables within and between drug groups and across exercise intensities. When a significant main effect was found (α = 0.05), the Holm-Sidak method was used for alpha adjustment and post hoc analysis. To further explore the relationship between absolute work rate and the hemodynamic effects of ET-1 receptor blockade at higher exercise intensities, we also evaluated responses at 80% of maximal work rate in those participants whose maximal work rate was greater than 15 W (n = 8, young; n = 5, old). Linear regression analysis was performed on individual data, with the slope and y-intercept determined to evaluate the increase in leg blood flow, MAP, and leg vascular conductance in response to BQ-123 infusion across work rates. A paired t test was used to compare the effect of BQ-123-induced changes on slope and y-intercept values. All group data are expressed as mean ± SE.
Results
Participant Characteristics
Participant characteristics are presented in Table 1 . All participants were normotensive, with lab values within normal range.
Resting Responses
Prior to BQ-123 administration, resting leg blood flow was significantly lower in the old compared with the young (Figure 2 ). In both young and old groups, the continuous administration of the ET A receptor antagonist BQ-123 (10 nmol/min/L of thigh volume; infusion rate: 0.8-1.5 mL/min) did not significantly change heart rate (Δ −2 ± 3 bpm, young; Δ −4 ± 2 bpm, old) or MAP (Δ −1 ± 3 mmHg, young; Δ −2 ± 2 mmHg, old) after 45 minutes of infusion. However, BQ-123 did provoke a significant increase in leg blood flow ( Figure 2 ) and leg vascular conductance in the old (Δ + 0.9 ± 0.3 mL/min/mmHg) but not in the young (Figure 2 ; Δ 0.0 ± 0.4 mL/min/ mmHg). This observed BQ-123-mediated increase leg blood flow effectively restored leg blood flow in the old to that of the young (Figure 2 ).
Exercise Responses
A subset of the exercise data investigating the contribution of the ET A receptor in the regulation of vascular tone in the young during knee-extensor exercise of absolute work rates has been previously reported (18) . This study extends these previously published findings through inclusion of absolute and relative exercise intensities, as well as quantifying the association between work rate and BQ-123-Induced changes in leg blood flow, MAP, and leg vascular conductance. A significant difference in delta leg blood flow was observed between young and old (p < .001). The slope of the relationship between BQ-123-induced increases in leg blood flow and work rate was significantly greater in the old compared with the young (+29 ± 3 and +16 ± 3 mL/min/W, respectively, p = .037; Figure 3 , bottom). A significant difference in delta leg vascular conductance was also observed between young and old (p < .001). The slope of the relationship between BQ-123-induced increases in leg vascular conductance and work rate was significantly greater in the old compared with the young (+0.14 ± 0.02 vs +0.26 ± 0.03 mL/ min/mmHg/W, respectively, p = .012; Figure 4 , bottom). Delta MAP was similar between groups (p = .605), with the slope of the relationship between the BQ-123-induced reductions in MAP and work rate significantly greater in the old compared with the young (−0.16 ± 0.02 vs −0.08 ± 0.02 mmHg/W, respectively, p = .032; Figure 5 , bottom). In both the young and the old, the vasodilation provoked by BQ-123 during exercise contributed to an increase in leg VO 2 (Tables 2 and 3) . No significant changes in net lactate release or pH were observed during BQ-123 infusion compared with the saline trial (Tables 2 and 3 ).
Exercise Time Control Study
Fifteen of the original 17 participants (n = 8 young; n = 7 old) who participated in the drug infusion protocol returned to the lab for an exercise time control protocol. There was no significant difference in leg blood flow or MAP between the two exercise bouts (Figure 6 ). Using this time control study and the one exercise bout (saline trial) from the catheter-based study day, we identified a within-participant coefficient of variation for leg blood flow of 3%-4% across work rates in both young and old groups. Leg blood flow (top) and BQ-123-induced changes in leg blood flow (bottom) during exercise in young (circles) and old (diamonds) participants. Data at the highest work rate (80% of maximum) represents the leg blood flow response in those participants whose maximal work rate was greater than 15 W (n = 8, young; n = 5, old). *Significant difference from saline in both the young and the old, p < .05; **significant difference from saline in the old, p < .05; +significant difference from BQ-123-induced changes at rest in both the young and old, p < .05; ++significant difference from saline in the old, p < .05; ‡ significant difference from young, p < .05.
Discussion
This study has identified a functional role of the ET A vasoconstrictor pathway in the regulation of vascular tone with advancing age. At rest, ET A blockade reversed the age-associated reduction in leg blood flow, confirming a significant contribution of the ET A receptor to the elevation in resting vascular tone in the elderly. During exercise, ET A receptor inhibition augmented leg blood flow to a greater degree in the old compared with young, demonstrating an age-associated increase in ET A -mediated restraint of exercising skeletal muscle blood flow. ET A blockade also attenuated the exerciseinduced increase in arterial blood pressure to a greater degree in the old compared with their younger counterparts. These hemodynamic changes were accompanied by increases in leg VO 2 in both groups, suggesting a decrease in intramuscular efficiency in the presence of ET A blockade. Taken together, these findings have identified an agerelated increase in resting ET A vasoconstrictor activity that persists . Leg vascular conductance (top) and BQ-123-induced changes in leg vascular conductance (bottom) during exercise in young (circles) and old (diamonds) participants. Data at the highest work rate (80% of maximum) represents the leg blood flow response in those participants whose maximal work rate was greater than 15 W (n = 8, young; n = 5, old). *Significant difference from saline in both the young and the old, p < .05; +significant difference from BQ-123-induced changes at rest in both the young and old, p < .05; ++significant difference from saline in the old, p < .05; ‡ significant difference from young, p < .05. during exercise, suggesting an important role of this pathway in the regulation of skeletal muscle blood flow and arterial blood pressure during physical activity with advancing age.
ET A Receptor-Mediated Restraint of Skeletal Muscle Blood Flow at Rest
A number of studies from our group (7, 29) and others (1, 3, 33, 34) have collectively demonstrated that healthy aging is associated with a reduction in resting limb blood flow. Although there are many structural, autonomic, and neuroendocrine factors responsible for the decline in blood flow, findings from this study implicate the ET-1 pathway as a significant contributor to this age-related change. As presented in Figure 2 , we observed an approximately 30% reduction in resting leg blood flow in the old compared with their younger counterparts. Administration of BQ-123 did not affect leg blood flow in the young group, but in the elderly, it resulted in a progressive increase in leg blood flow that ultimately restored resting leg blood flow to a level that was similar to the young (Figure 2) . Interestingly, prior to BQ-123 administration, net ET-1 release was similar between groups (Tables  2 and 3 ). However, following ET A receptor blockade, circulating ET-1 increased almost twofold in the old but remained unchanged in the young (Tables 2 and 3 ). This suggests that present findings build upon recent studies reporting a significantly greater contribution of the ET A receptor to vascular tone in the old compared with the young at rest (15, 16) , but with the important addition of arterial and venous ET-1 levels, data that provide further insight concerning the relationship between circulating ET-1 and hemodynamic measurements. Together, these former and present findings present an aging vascular phenotype characterized by an increase in the endogenous contribution of ET-1 to vascular tone, accompanied by an overall increase in bound ET-1 and/or enhanced ET-1 bioavailability in old individuals.
ET A Receptor-Mediated Restraint of Skeletal Muscle Blood Flow during Exercise
From rest to exercise, perfusion of the exercising skeletal muscle increases dramatically in order to match the metabolic demand of Figure 5 . Mean arterial pressure (top) and BQ-123-induced changes in mean arterial pressure (bottom) during exercise of relative intensity work rates in young (circles) and old (diamonds). *Significant difference from saline in both the young and the old, p < .05; +significant difference from BQ-123-induced changes at rest in both the young and old, p < .05; ‡ significant difference from young, p < .05. the active muscle, achieved through the vasoconstriction of less metabolically active tissue and the modulation of vasodilator and vasoconstrictor influences within the exercising muscle vasculature (35) . With advancing age, there is an apparent shift in favor of greater vasoconstriction during exercise, resulting in attenuation of exercise hyperemia (4, (8) (9) (10) . Based on these previous findings and on the known role of ET A inhibition to modulate vascular tone in the elderly at rest (Figure 2) (15,16) , the ET-1 pathway seems a likely contributor to blood flow regulation during exercise in this cohort.
In this study, the old exhibited a progressively greater increase in leg blood flow and leg vascular conductance with increasing absolute exercise intensities following ET A receptor blockade, compared with the young (Figures 3 and 4) . The attenuation in the exercise-induced increase in MAP with BQ-123 also displayed a progressively greater age-associated difference, with the old exhibiting greater BQ-123-induced reductions in MAP with increasing relative work rates ( Figure 5 ). These age-specific cardiovascular responses following BQ-123 are in contrast to the only other published study examining the effect of ET A receptor blockade on exercising limb blood flow. McEniery and coworkers (36) evaluated forearm blood flow during static intermittent handgrip exercise in middle-aged, hypertensive, and normotensive individuals before and after intra-arterial (brachial) BQ-123 administration and reported no difference between the blocked and control trials in the normotensive group, suggesting the ET A receptor did not contribute significantly to the modulation of vascular tone during handgrip exercise. However, although this previous study included a wide age range (30-50 years), it was not designed to examine age-related changes in limb blood flow in the response to BQ-123. Thus, the present findings substantially extend this earlier work, clearly identifying the ET A pathway as an important component in age-associated changes in the cardiovascular response to dynamic exercise.
Improved Exercising Muscle Blood Flow and Intramuscular Efficiency
The increase in leg blood flow following ET A receptor blockade was accompanied by a comparable decline in intramuscular efficiency during exercise in both groups, as evident by greater leg VO 2 for a similar amount of work (Tables 2 and 3 ). These data indicate that in both young and old, the maintenance of vascular tone not only is vital in the support of MAP but also might play a role in limiting the perfusion of the exercising muscle during submaximal work in order to prevent an exaggerated O 2 delivery in excess of metabolic demand. This increase in leg VO 2 induced by ET A receptor blockade occurred in the absence of an alteration in net lactate release (Tables  2 and 3) , further suggesting that the increase in leg blood flow following BQ-123 did not appear to confer beneficial effect on muscle metabolism. Thus, it appears that the ET A pathway may provide an important governing influence on exercising limb blood flow in the elderly in order to optimize the matching of blood flow with metabolic demand in the exercising skeletal muscle.
Perspectives
This study has identified a functional role of the ET A vasoconstrictor pathway in the regulation of vascular tone during exercise in older, healthy adults. To our knowledge, this is the first study to perform ET A receptor inhibition during exercise in the elderly and to report a greater augmentation in leg blood flow in the old compared with young in response to ET A blockade. These findings demonstrating an age-associated increase in ET A -mediated restraint of exercising skeletal muscle blood flow add significantly to our understanding of how this pathway contributes to the sequelae of vascular dysfunction in the elderly. The high prevalence of exercise intolerance in the elderly (37) , coupled with the recognition of inactivity as a risk factor in the development of cardiovascular disease (38) , makes findings from this study highly relevant to the growing body of literature linking excessive vascular tone and impaired capacity for physical activity in older, healthy adults.
Although there are several factors that may modulate ET Amediated vasoconstriction during exercise in the elderly, one noteworthy candidate is the vasodilator nitric oxide (NO). Indeed, it is now well established that NO may limit the production and action of ET-1 (39, 40) , a reciprocal relationship that may be particularly relevant to age-related changes in the regulation of exercising skeletal Table 3 . Impact of BQ-123 Infusion on Selected Physiological Variables at Rest and During Relative Intensity Exercise muscle blood flow. Although there is some ambiguity in the literature regarding the importance of NO release on exercising muscle blood flow (41) (42) (43) (44) , recent work from our group identified a marked reduction in forearm blood flow during handgrip exercise following intraarterial (brachial) administration of the nitric oxide synthase inhibitor L-NMMA (21) . This finding in young, healthy humans suggests that the NO pathway contributes significantly to hyperemia of the exercising skeletal muscle and thus may play an important role in opposition to vasoconstrictor pathways such as ET-1. Thus, considering the agerelated decline in NO-mediated vasodilation present at rest (45) and during exercise (46) , it is tempting to speculate that a reduction in NO bioavailability in the elderly may be partially responsible for the exaggerated increase in leg blood flow following ET A receptor inhibition ( Figure 3) . However, further studies utilizing both NO and ET A antagonism are required to further explore this interesting possibility.
Experimental Considerations
Due to the slow acting kinetics of BQ-123 binding and clearance, the study was ordered so the control (saline) trial always preceded the BQ-123 trial. However, a time control trial on a separate day demonstrated comparable measurements of leg blood flow and MAP during repeated bouts of knee-extensor exercise (Figure 6 ), providing confidence in the comparison of the control and the BQ-123 trials. We cannot exclude the possibility that some of the observed changes in peripheral hemodynamics are due to ET-1 subtype B (ET B ) receptor activation, as BQ-123 is highly selective for ET A receptors. A recent study utilizing combined ET A and ET B receptor inhibition in the arm vasculature have failed to identify a significant role for ET B receptors in the regulation of vascular tone in humans (16) . However, with the recognition that significant limb specificity exists in the regulation of vascular tone (47) , additional studies utilizing both ET A and ET B inhibitions are required to fully characterize the role of ET-1 during lower limb exercise in the elderly. Finally, although all participants were identified as normally active, we acknowledge that differences in aerobic fitness between groups may have influenced the observed exercising leg blood flow responses.
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